<code id='E79618E1A9'></code><style id='E79618E1A9'></style>
      • <acronym id='E79618E1A9'></acronym>
      <center id='E79618E1A9'><center id='E79618E1A9'><tfoot id='E79618E1A9'></tfoot></center><abbr id='E79618E1A9'><dir id='E79618E1A9'><tfoot id='E79618E1A9'></tfoot><noframes id='E79618E1A9'>
      • <optgroup id='E79618E1A9'><strike id='E79618E1A9'><sup id='E79618E1A9'></sup></strike><code id='E79618E1A9'></code></optgroup>
        5. <b id='E79618E1A9'><label id='E79618E1A9'><select id='E79618E1A9'><dt id='E79618E1A9'><span id='E79618E1A9'></span></dt></select></label></b><u id='E79618E1A9'></u>
          <i id='E79618E1A9'><strike id='E79618E1A9'><tt id='E79618E1A9'><pre id='E79618E1A9'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-30 02:32:54 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：55
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Do masks work? RCTs can't tell us
                                
                            
          Next article：  
                                      
                                          Heart attack and stroke risk calculators need revising
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles